First Trimester Screening with Pre-eclampsia risk Report

Patient Name Kriti Kumari Jha Sample type SERUM

Date of Birth / Age 19-11-1995 / 28Yrs Sample Collection Date 11-06-2024

Requesting Clinician Dr. Venus Bansal Sample Receiving Date 12-06-2024

Order ID/Sample ID 964414/8549079 Report Date 14-06-2024

Biochemical parameters Value Unit

hCGb 65.41 ng/ml
Method: Time resolved Fluro-immunoassay

PAPP A 1544.6 mU/L

Method: Time resolved Fluro-immunoassay

PIGF 65.78 pg/mL

Method: Time resolved Fluro-immunoassay
hCGb:Free Beta Human Chorionic Gonadotropin, PAPP A:Pregnancy associated Plasma Protein A, PIGF: Placental Growth Factor

Results

Condition Final Risk Cut-off Risk assessment

Trisomy 21 1:5534 1:250 Low risk
Trisomy 18 1:100000 1:100 Low risk
Trisomy 13 1:100000 1:100 Low risk
Pre-eclampsia <32 1:4836 1:100 Low risk
Pre-eclampsia <34 1:1109 1:100 Low risk
Pre-eclampsia <37 1:169 1:100 Low risk
Interpretation :
The given sample is SCREEN NEGATIVE for Trisomy 21,Trisomy 18,Trisomy 13 and Pre-eclampsia.
Disclaimer :
Screen positive or screen negative is based on probability cut-off. This screening provides an estimation of risk, not a diagnosis. A screen negative result doesn't exclude the possibility of Down
syndrome or other abnormalities. A screen positive result doesn't mean the fetus is affected but warrants further investigations before a diagnosis can be confirmed (an unaffected fetus may have
screen-positive result for unknown reasons). An intermediate risk result for Trisomy 21 (risk between 1:251 to 1:1000) means that the pregnancy has an equivocal or a borderline risk of being
affected with the condition. In such a case non-invasive prenatal testing may be done before taking a decision on an invasive confirmatory testing.
Incorrect or incomplete information may significantly alter results. This interpretation assumes that patient, specimen details and ultrasound details are accurate and correct. In particular, erroneous
assessment of gestational age can result in false-positive or false-negative screen results. Because of its increased accuracy, the determination of gestational age by ultrasound is recommended,
when possible, rather than by last menstrual period. We strongly recommend that NT/CRL measurements are performed as per FMF (UK)/ISUOG practice guidelines. MedGenome doesn’t bear
responsibility for the ultrasound marker values provided by the customers.
Race, weight, smoking, multiple fetus pregnancy, insulin-dependent diabetes (IDD), and in vitro fertilization (IVF) may affect marker concentrations.
Results may be unreliable in twin pregnancies with a fetal demise.
The risk estimate for Downs Syndrome in a twin pregnancy is only a guide since the calculation relies on making assumptions on the distribution of markers in affected twin pregnancies.
Following parameters are known to affect the analysis of the hormones: Hemolysis, Lipemia, Heterophile antibodies, Prolonged storage at incorrect temperature, Serum contaminated with EDTA,
Citrate and Heparin. High concentrations (above therapeutic levels) of calcium, gamma globulin, and acetylsalicylic acid may interfere with the assay. Complement activation may in some rare
cases give falsely low results in PIGF. Valid measurements of AFP in maternal serum cannot be made after amniocentesis. As in any medical testing, there is always a chance of failure or error in
sample analysis though extensive measures are taken to avoid these errors.
Intermediate risk cutoffs have been adapted from Muñoz-Cortes et al. (2012), Contingent screening for Down syndrome completed in the first trimester: a multicenter study. Ultrasound Obstet
Gynecol, 39: 396-400.
Laboratory reported risk shouldn’t be interpreted in isolation, it should be correlated and adjusted to the absence/presence of sonographic markers observed in the anomaly/malformation scan and
other relevant clinical findings. Any recommendation for genetic counselling or guidance for additional diagnostic testing like amniocentesis or chorionic villus sample is the responsibility of the
healthcare provider.
Hormone values have been analyzed utilizing technology and kits approved by Fetal Medicine Foundation (FMF), UK with appropriate quality control measures. Screening risks have been
generated from Lifecycle software validated by the FMF and the ASPRE FMF pre-eclampsia algorithm.

Dr. Parul Kansal

Clinical Pathologist

End of Report

Sample ID & Name : 8549079 & Kriti Kumari Jha

Test performed at : MedGenome Labs Ltd, MEDGENOME- BANGALORE
Page 1 of 1
MedGenome Labs Ltd.,
Tower-1, Veerasandra Village, Electronic City, Phase-1, Bangalore, Karnataka, 560100.
Maternal Serum Screening

PATIENT REPORT - Kriti Kumari Jha 14/06/2024

Patient 964414: -, Kriti Kumari Jha

PATIENT ID: LAST NAME: FIRST NAME: BIRTH DATE:
964414 - Kriti Kumari Jha 19/11/1995
ETHNICITY: ADDRESS 1:
South Asian -

Pregnancy, Calculated EDD: 17/12/2024 (MAEDD: 29.08)

MAEDD: CALCULATED EDD: GEST. DATE: SELECTED GEST. METHOD:
29.08 17/12/2024 12/03/2024 CRL
LMP DATE: SMOKING STATUS: INSULIN DEP. DIABETIC: NO. OF FETUSES:
20/03/2024 Non smoker No 1
MONOZYGOUS: CHORIONICITY: CORRECTED BY CHORIONICITY: MATERNAL WEIGHT [KG]:
No - - 70
HEIGHT [CM]: DIABETES TYPE II: INSULIN TREATMENT FOR TYPE II DIABETES: CONCEPTION METHOD:
161 - - Spontaneous
MOTHER OF PATIENT HAD PRE-ECLAMPSIA: CHRONIC HYPERTENSION: SYSTEMIC LUPUS ERYTHEMATOSUS: ANTI-PHOSPHOLIPID SYNDROME:
- - - -
PREV. PREG. PRE-ECLAMPSIA: ASSISTANCE METHOD: TRANSFER DATE: EGG EXTRACTION DATE:
- - - -
EGG DONOR DOB: AGE AT EXTRACTION: PAST T21 - DOWN'S SYNDROME: PAST T18 - EDWARDS' SYNDROME:
- - - -
PAST T13 - PATAU'S SYNDROME: PAST NTD: PAST CDLS - CORNELIA DE LANGE SYNDROME: PAST SLOS - SMITH-LEMLI-OPITZ SYNDROME:
- - - -
RISK ASSESSED:
At term

Biochemistry
SAMPLE ID: SPECIMEN COLLECTED: SPECIMEN RECEIVED: GEST. AT SAMPLE DATE (W + D):
8549079 11/06/2024 12/06/2024 13 w 0 d

Ultrasound
SCAN DATE: CRL: BPD: HC:
11/06/2024 66.6 - -
GEST. AT SAMPLE DATE (W + D): CRL (#2): BPD (#2): HC (#2):
13 w 0 d - - -
GEST. AT MANUAL ENTRY (W + D): WEIGHT [KG]: AC: AC (#2):
0w0d - - -

Blood pressure, Gest. at sample date (w + d): 13 w 0 d

TIME MEASURED: LEFT SYST #1: LEFT DIAST #1: LEFT SYST #2: LEFT DIAST #2: MAP [MMHG]:
11/06/2024 120 80 - - 93.33
WEIGHT [KG]: RIGHT SYST #1: RIGHT DIAST #1: RIGHT SYST #2: RIGHT DIAST #2: CORR. MOM:
70 - - - - 1.08

Tests
TEST SAMPLE ID DATE GEST. AT SAMPLE VALUE UNIT CORR. MOM WEIGHT [KG]
DATE (W + D)
hCGb (Signed) 8549079 11/06/2024 13 w 0 d 65.41 ng/mL 1.95 70

PAPP-A (Signed) 8549079 11/06/2024 13 w 0 d 1544.6 mU/L 0.5 70

PlGF (Signed) 8549079 11/06/2024 13 w 0 d 65.78 pg/mL 1.15 70

NB (Signed) - 11/06/2024 13 w 0 d Present - - -

NT (Signed) - 11/06/2024 13 w 0 d 1.5 mm 1.07 -

UTPi (Signed) - 11/06/2024 13 w 0 d 1.4 - 0.95 -

1/2
MedGenome Labs Ltd.,
Tower-1, Veerasandra Village, Electronic City, Phase-1, Bangalore, Karnataka, 560100.
Maternal Serum Screening

PATIENT REPORT - Kriti Kumari Jha 14/06/2024

Risks, Risk assessed: At term
RISK NAME: RISK RESULT: RISK: TWIN RISK RESULT: TWIN RISK: AGE RISK: CUT-OFF:
T21 (Calculated) Low 1:5534 - - 1:1063 1:1000
RISK NAME: RISK RESULT: RISK: TWIN RISK RESULT: TWIN RISK: AGE RISK: CUT-OFF:
T18 (Calculated) Low 1:100000 - - 1:9561 1:100
RISK NAME: RISK RESULT: RISK: TWIN RISK RESULT: TWIN RISK: AGE RISK: CUT-OFF:
T13 (Calculated) Low 1:100000 - - 1:28710 1:100
RISK NAME: RISK RESULT: RISK: TWIN RISK RESULT: TWIN RISK: AGE RISK: CUT-OFF:
PE < 32 (Calculated) Low 1:4836 - - 1:811 1:100
RISK NAME: RISK RESULT: RISK: TWIN RISK RESULT: TWIN RISK: AGE RISK: CUT-OFF:
PE < 34 (Calculated) Low 1:1109 - - 1:320 1:100
RISK NAME: RISK RESULT: RISK: TWIN RISK RESULT: TWIN RISK: AGE RISK: CUT-OFF:
PE < 37 (Calculated) Low 1:169 - - 1:93 1:100

....This is an electronically authenticated report....

2/2